This double-blind, placebo-controlled trial (n=43) aimed to assess the effectiveness of combining intravenous ketamine with mindfulness exercises in treating unipolar depression.
Conducted by Rebecca Price at the University of Pittsburgh, the study involved administering a single infusion of intravenous ketamine to depressed patients, who were then randomized into two groups: one receiving mindfulness training and exercises alongside the infusion, and the other receiving typical infusion conditions.
The primary outcome measure was the reduction in depression following the infusion, assessed using the Montgomery-Asberg Depression Rating Scale. Secondary measures included self-reported mindfulness, spiritual experiences, and attentional bias. Participants, aged 18 to 65, needed to score ≥14 on the Hamilton Depression Rating Scale and have no history of certain conditions or recent changes in treatment. The study began in February 2022 and concluded in September 2023.
Trial Details
In this project, the investigators will administer a single infusion of IV ketamine to depressed patients and randomize the patients to receive either a) usual/typical infusion conditions or b) mindfulness training and exercises in conjunction with the infusion. Investigators will test whether the conjunction of ketamine + mindfulness enhances the reductions in depression following a single ketamine infusion.Trial Number NCT05168735
Sponsors & Collaborators
University of PittsburghThis company doesn't have a full profile yet, it is linked to a clinical trial.